Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial.
Saved in:
| Title: | Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial. |
|---|---|
| Authors: | Mo ZJ; Expanded Program on Immunization Department, Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China., Bi ZF; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Sheng W; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Chen Q; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Huang T; Expanded Program on Immunization Department, Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China., Li MQ; Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China., Cui XL; Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China., Wangjiang YH; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Lin BZ; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China., Zheng FZ; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China., Sun G; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China., Li YF; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Zheng Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Zhuang SJ; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Su YY; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Pan HR; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China., Huang SJ; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Wu T; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Zhang J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China., Xia NS; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China. |
| Source: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Nov 30; Vol. 18 (6), pp. 2092363. Date of Electronic Publication: 2022 Jul 14. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35834812 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Mo+ZJ%22">Mo ZJ</searchLink>; Expanded Program on Immunization Department, Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China.<br /><searchLink fieldCode="AU" term="%22Bi+ZF%22">Bi ZF</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Sheng+W%22">Sheng W</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Chen+Q%22">Chen Q</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Huang+T%22">Huang T</searchLink>; Expanded Program on Immunization Department, Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China.<br /><searchLink fieldCode="AU" term="%22Li+MQ%22">Li MQ</searchLink>; Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China.<br /><searchLink fieldCode="AU" term="%22Cui+XL%22">Cui XL</searchLink>; Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China.<br /><searchLink fieldCode="AU" term="%22Wangjiang+YH%22">Wangjiang YH</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Lin+BZ%22">Lin BZ</searchLink>; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Zheng+FZ%22">Zheng FZ</searchLink>; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Sun+G%22">Sun G</searchLink>; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Li+YF%22">Li YF</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Zheng+Y%22">Zheng Y</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Zhuang+SJ%22">Zhuang SJ</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Su+YY%22">Su YY</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Pan+HR%22">Pan HR</searchLink>; Vaccine R&D Department, Xiamen Innovax Biotech Company, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Huang+SJ%22">Huang SJ</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Wu+T%22">Wu T</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Zhang+J%22">Zhang J</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China.<br /><searchLink fieldCode="AU" term="%22Xia+NS%22">Xia NS</searchLink>; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, Xiamen University, Xiamen, Fujian, China. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101572652%22">Human vaccines & immunotherapeutics</searchLink> [Hum Vaccin Immunother] 2022 Nov 30; Vol. 18 (6), pp. 2092363. <i>Date of Electronic Publication: </i>2022 Jul 14. – Name: TypePub Label: Publication Type Group: TypPub Data: Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101572652 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2164-554X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221645515%22">21645515 </searchLink><i>NLM ISO Abbreviation: </i>Hum Vaccin Immunother <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35834812 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/21645515.2022.2092363 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2092363 Titles: – TitleFull: Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Mo ZJ – PersonEntity: Name: NameFull: Bi ZF – PersonEntity: Name: NameFull: Sheng W – PersonEntity: Name: NameFull: Chen Q – PersonEntity: Name: NameFull: Huang T – PersonEntity: Name: NameFull: Li MQ – PersonEntity: Name: NameFull: Cui XL – PersonEntity: Name: NameFull: Wangjiang YH – PersonEntity: Name: NameFull: Lin BZ – PersonEntity: Name: NameFull: Zheng FZ – PersonEntity: Name: NameFull: Sun G – PersonEntity: Name: NameFull: Li YF – PersonEntity: Name: NameFull: Zheng Y – PersonEntity: Name: NameFull: Zhuang SJ – PersonEntity: Name: NameFull: Su YY – PersonEntity: Name: NameFull: Pan HR – PersonEntity: Name: NameFull: Huang SJ – PersonEntity: Name: NameFull: Wu T – PersonEntity: Name: NameFull: Zhang J – PersonEntity: Name: NameFull: Xia NS IsPartOfRelationships: – BibEntity: Dates: – D: 30 M: 11 Text: 2022 Nov 30 Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 2164-554X Numbering: – Type: volume Value: 18 – Type: issue Value: 6 Titles: – TitleFull: Human vaccines & immunotherapeutics Type: main |
| ResultId | 1 |
